Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

DOI Web Site Web Site 2 Citations

Journal

  • The Lancet

    The Lancet 399 (10333), 1383-1390, 2022-04

    Elsevier BV

Citations (2)*help

See more

Report a problem

Back to top